Basic and Clinical Neuroscience, 2022 · DOI: http://dx.doi.org/10.32598/bcn.2021.1422.1 · Published: September 1, 2022
This review investigates the role of Chondroitinase ABC (ChABC) in improving complications following Spinal Cord Injuries (SCI). A total of 34 preclinical studies were included. Our results showed that ChABC administration improves locomotion recovery after SCI. The findings of the present study showed that prescribing ChABC has a moderate effect in improving locomotion after SCI in mice and rats. However, this moderate effect introduces ChABC as adjuvant therapy and not as primary therapy.
ChABC is more effective as an adjuvant therapy, used in combination with other treatments, rather than a primary therapy for spinal cord injuries.
ChABC's primary mechanism involves restoring neuronal plasticity in the spinal cord by digesting CSPGs and promoting axonal regeneration.
Future studies should focus on the effects of combining ChABC with other therapeutic approaches, such as stem cells or laser therapy, to enhance its effectiveness.